

# Pfizer Declares Second-Quarter 2024 Dividend

Wednesday, April 24, 2024 - 04:37pm

## ***Board of Directors approves quarterly cash dividend of \$0.42 per share***

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a \$0.42 second-quarter 2024 dividend on the company's common stock, payable June 14, 2024, to holders of the Common Stock of record at the close of business on May 10, 2024. The second-quarter 2024 cash dividend will be the 342nd consecutive quarterly dividend paid by Pfizer.

## ***About Pfizer: Breakthroughs That Change Patients' Lives***

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at [www.Pfizer.com](http://www.Pfizer.com). In addition, to learn more, please visit us on [www.Pfizer.com](http://www.Pfizer.com) and follow us on X at [@Pfizer](https://twitter.com/Pfizer) and [@Pfizer News](https://twitter.com/PfizerNews), [LinkedIn](https://www.linkedin.com/company/pfizer), [YouTube](https://www.youtube.com/channel/UCv33333333333333333333) and like us on Facebook at [Facebook.com/Pfizer](https://www.facebook.com/Pfizer).

Category: Corporate, Finance

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240424881798/en/): <https://www.businesswire.com/news/home/20240424881798/en/>

Media:

[PfizerMediaRelations@Pfizer.com](mailto:PfizerMediaRelations@Pfizer.com)

+1 (212) 733-1226

Investor:

[IR@Pfizer.com](mailto:IR@Pfizer.com)

+1 (212) 733-4848

Source: Pfizer Inc.